Oncologists rank favourite pharmas

HCPs in oncology have started valuing a broad portfolio of drugs when evaluating pharmas in the segment rather than huge blockbusters, according to the latest survey released by ZoomRx.

In the most recent survey asking HCPs to rank 20 pharmas across five weighted dimensions AstraZeneca maintained top position by "offering a breadth of innovation that few can match" with deep pipelines across multiple tumour types, backed up by responsive support teams. It had an overall score of 47.

Meanwhile, Johnson & Johnson Innovative Medicine leapt from 7th place to equal 3rd place in the rankings with an overall score of 31. ZoomRx attributed this to J&J "delivering practice-changing innovation and proving they can alter treatment paradigms with first-in-class therapies".